We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

76 hedge funds and large institutions have $153M invested in KalVista Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 19

1% more funds holding

Funds holding: 75 → 76 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

11.74% less ownership

Funds ownership: 85.72% → 73.98% (-12%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

53% less capital invested

Capital invested by funds: $328M → $153M (-$175M)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
15
Increased
21
Reduced
19
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$2.91M
2
Northern Trust
Northern Trust
Illinois
+$1.69M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
+$1.47M
4
Squarepoint
Squarepoint
New York
+$851K
5
O
OrbiMed
New York
+$626K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$30.1M
2
DM
Deerfield Management
New York
-$5.28M
3
Invesco
Invesco
Georgia
-$4M
4
ACP
Acuta Capital Partners
California
-$3.04M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$130K -$4M -247,416 -96%
UBS Group
52
UBS Group
Switzerland
$124K +$139K +8,605 +409%
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$123K -$1.29K -80 -0.7%
GCP
54
GSA Capital Partners
United Kingdom
$120K +$167K +10,321 New
Citadel Advisors
55
Citadel Advisors
Florida
$118K -$176K -10,878 -52%
AllianceBernstein
56
AllianceBernstein
Tennessee
$117K +$163K +10,100 New
Deutsche Bank
57
Deutsche Bank
Germany
$101K -$8.55K -529 -6%
Bank of America
58
Bank of America
North Carolina
$90K +$41.5K +2,569 +50%
AIG
59
American International Group
New York
$86K -$808 -50 -0.7%
TRCT
60
Tower Research Capital (TRC)
New York
$45K +$59.5K +3,685 +1,919%
JP Morgan Chase
61
JP Morgan Chase
New York
$44K -$541K -33,481 -90%
TAM
62
Tiverton Asset Management
Delaware
$29K – – –
Legal & General Group
63
Legal & General Group
United Kingdom
$23K – – –
Victory Capital Management
64
Victory Capital Management
Texas
$20K +$28.1K +1,739 New
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$17.1K +$22.7K +1,406 +2,068%
FCM
66
Flinton Capital Management
Pennsylvania
$15K – – –
LC
67
Lindbrook Capital
California
$15K +$20.2K +1,250 New
AIP
68
Ameritas Investment Partners
Nebraska
$12K – – –
TAM
69
Tyers Asset Management
Texas
$12K – – –
Bank of Montreal
70
Bank of Montreal
Ontario, Canada
$12K +$776 +48 +5%
NA
71
Neuburgh Advisers
California
$10K – – –
CSS
72
Cubist Systematic Strategies
Connecticut
$9K -$18.1K -1,122 -59%
MCIM
73
Meadow Creek Investment Management
Georgia
$7K – – –
Citigroup
74
Citigroup
New York
$6K -$43.3K -2,681 -82%
VFA
75
Valeo Financial Advisors
Indiana
$2K – – –
1 2
3
4

KALV Hedge Fund Activity: Q3 2019 in Review

76 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2019, worth a combined $153M — down 53% from $328M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KALV positions and 14 closed out — a net gain of 1 holder — while 21 added to existing stakes and 19 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.91M. The largest seller was Vivo Capital, exiting entirely with an estimated $30.1M sold.

  • 76 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2019, up from 75 in Q2 2019.
  • Funds reported $153M of KalVista Pharmaceuticals stock for Q3 2019, down 53% quarter-over-quarter.
  • 15 funds opened new KalVista Pharmaceuticals positions in Q3 2019 and 14 closed out, a net change of +1 holder.
  • The largest KalVista Pharmaceuticals buyer in Q3 2019 was Eventide Asset Management, an estimated $2.91M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $30.1M sold.

Based on aggregated 13F filings for Q3 2019.